Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics. Metformin and phenformin, previously used in the treatment of diabetes, have been shown to have anticancer effects in various cancers, including breast, lung and prostate cancers. However, their molecular mechanisms are still unclear. In this study, we examined the effects of these drugs in chemoresistant rectal cancer cell lines. We found that SW837 and SW1463 rectal cancer cells were more resistant to ionizing radiation and 5-fluorouracil than 
| INTRODUC TI ON
Colorectal cancer (CRC) is the third most common malignant cancer and the 4th most frequent cause of cancer-related death worldwide. 1 Most patients with CRC are treated with surgery; however, adjuvant treatments, such as radiotherapy and chemotherapy, are also required. CRC is a complex disease with a variable clinical presentation and molecular characteristics in response to treatment, even in tumors with similar histopathological characteristics. 2 Therefore, because of a lack of treatment strategies specific for rectal cancer, adjuvant chemotherapy regimens for patients with CRC are often applied in the treatment of rectal cancer. Although combinations of many advanced therapies for CRC have accelerated early detection and improved survival, treatment of CRC, particularly rectal cancer, remains challenging and requires molecular targeted therapy. 3 Many studies have demonstrated that there is an association between type 2 diabetes (T2DM) and CRC. Metformin, a standard clinical drug used to treat T2DM, decreases the incidence of tumor development and increases the survival rates of patients with T2DM and various types of cancer, including breast, colon, lung and prostate cancers. 4 Another T2M drug, phenformin, has also been shown to have anticancer effects in several cancers, including lung cancer, lymphoma and breast cancer. 5 Although these drugs have been used for many years to treat T2DM, the mechanisms of action of these drugs in cancer are still unclear. Both of these drugs are known to function as AMP-dependent protein kinase (AMPK) agonists and inhibit complex I in the mitochondrial electron transport chain. 6 Moreover, metformin and phenformin inhibit cell proliferation, angiogenesis, the epithelial-mesenchymal transition (EMT) and tumor growth in various cancers, including breast cancer, prostate cancer, lung cancer, melanoma, ovarian cancer and colon cancer. [7] [8] [9] [10] [11] [12] In colon cancer, metformin and phenformin inhibit the proliferation of CRC cells by blocking glycolysis, activating AMPK and stimulating reactive oxygen species production. [13] [14] [15] Indeed, in vivo studies have demonstrated the selective suppression of tumor growth in p53-deficient tumor cell xenografts. 16 However, other mechanisms of metformin and phenformin in rectal cancer have not been elucidated.
Transforming growth factor (TGF) β receptor type 2 (TGFBR2), a member of the TGF-β/Smad pathway, is involved in tumorigenesis. The expression of TGFBR2 is altered in various malignancies, including metastatic breast cancer, 17 CRC 18 and prostate cancer. 19 TGF-β signaling is an important pathway contributing to cancer development and has various functions in the regulation of cell growth, differentiation, apoptosis, EMT, angiogenesis and metastasis in a cellular context-dependent manner. 20, 21 Accumulating evidence has demonstrated that the EMT is a highly conserved developmental process in which the properties of epithelial cells are lost, and cells acquire the properties of mesenchymal cells, exhibiting an invasive phenotype. 22 Therefore, the EMT can regulate the invasion, metastasis, and therapeutic resistance of cancer cells, making it a promising target for cancer therapy.
In this study, we evaluated the effects of metformin and phenformin on apoptosis and the EMT in rectal cancer cells. Our findings suggested that metformin and phenformin represent effective therapeutic agents for the treatment of chemoresistant rectal cancer.
| MATERIAL S AND ME THODS

| Cell culture and chemical reagents
The rectal cancer cell lines SW837 and SW1463 and the colon cancer cell lines HCT116 and LS513 were obtained from the ATCC.
Rectal and colon cancer cell lines were cultured in Leibovitz's 15
(Welgene) at 37°C in an atmosphere containing 1% CO 2 or in RPMI 1640 (Lonza) at 37°C in an atmosphere containing 5% CO 2 containing 10% FBS (Corning) and gentamycin (50 μg/mL; Lonza), respectively.
5-Fluorouracil (5-FU), TGFBR inhibitor (SB525334), metformin and phenformin were obtained from Sigma-Aldrich. The signal transducer and activator of transcription 3 (STAT3) inhibitor STATTIC was purchased from Calbiochem. For assessing apoptosis, apoptotic protein assay (ARY009) was purchased and was performed according to the instructions provided using the R&D system.
| Irradiation
Colon and rectal cancer cells were irradiated with a 137Cs laboratory γ-irradiator (Gammacell 3000 Elan; MDS Nordion) at a dose rate of 3.25 Gy/min for the time required to apply a prescribed dose at room temperature.
| Apoptosis assay by flow cytometry (FACS) and immunofluorescence
Apoptosis analysis was performed using an FITC Annexin V Apoptosis 
| Western blot analysis
| Cell survival assays
MTT assays were conducted using HCT116, LSD513, SW837 and 
| Colony forming assay
| Transwell assays
| Human tissue microarray with immunohistochemical staining
Human colon cancer tissue microarray slides were obtained from AccuMax ISU ABXIS and contained 32 colon cancer specimens.
After baking and deparaffinization, the slides were boiled in a pres- 
| Xenograft mouse studies
All animal experiments were approved and performed in accordance 
| Statistical analysis
Statistical significance of the differences between mean values was calculated with unpaired Student's t tests using SPSS (version 12.0; SPSS Inc.) or Excel (Microsoft) software packages. Results with Pvalue of <0.05 were considered statistically significant.
| RE SULTS
| Rectal cancer cells were resistant to ionizing radiation and 5-fluorouracil treatment
Because Collectively, these results indicated that SW837 and SW1463 rectal cancer cells were more resistant to IR-and 5-FU-induced apoptosis.
| Metformin and phenformin increased apoptotic cell death in rectal cancer cells
Because metformin and phenformin have been found to have potential applications as anticancer drugs in various cancer cell lines [7] [8] [9] [10] [11] [12] and metformin has been shown to have positive clinical outcomes in patients with T2DM and CRC, 4 we next examined whether met- Moreover, inhibition of TGF-β/Smad signaling by SB525334 or siRNA had no effect on the expression of antiapoptotic proteins ( Figure 3H ).
Collectively, our data suggested that STAT3 signaling, but not TGF-β/ Smad signaling, contributed to apoptosis in rectal cancer.
| Metformin and phenformin inhibited the epithelial-mesenchymal transition by blocking of transforming growth factor-β receptor type 2 expression in rectal cancer cells
To 
| Phospho-STAT3 (Ser-727) and transforming growth factor-β receptor type 2 levels in human colon and rectal cancer tissues
In previous studies, phospho-STAT3 (Ser-727) and TGFBR2 have been shown to act as oncogenes in various cancers, including breast, lung, colorectal and prostate cancers. 19, [26] [27] [28] However, their roles in rectal cancer are unclear. We therefore determined by western analysis that the expression of STAT3 (Ser-727) and TGFBR2 are decreased in mouse tumor tissues treated with metformin and phenformin, as shown in Figure 2F ( Figure S1 ). In addition, we first investigated differences in the expression levels of phospho-STAT3 (Ser-727) and TGFBR2 in CRC, including 32 colon cancer cases and 73 rectal cancer cases. The levels of phospho-STAT3 (Ser-727) and TGFBR2 were increased in CRC ( Figure 5A,B) . Collectively, these results supported that 
| D ISCUSS I ON
In this study, we showed that metformin and phenformin decreased the expression of pro-apoptotic proteins by inhibiting STAT3 phosphorylation at Ser-727 and suppressed invasion and migration by inhibiting TGFBR2-mediated signaling. These data demonstrated, for the first time, that rectal cancer progression, including apoptosis, invasion and migration, was controlled by metformin-and phenformin-mediated phospho-STAT3 (Ser-727) and TGFBR2 signaling.
A proposed working model for metformin and phenformin in rectal cancer progression is presented in Figure 5C .
Recent epidemiological studies have demonstrated that metformin and phenformin play important roles in cancer progression 5, 29 ; however, the molecular mechanisms underlying this effect are unclear. AMPK-dependent signaling has been shown to mediate the effects of metformin and phenformin on cell growth. In bladder cancer, especially, metformin or phenformin and gefinitib, a well-known EGFR tyrosine kinase inhibitor, cooperated to inhibit cell growth via AMPK and EGFR pathways. 30, 31 However, this mechanism was not active in our system; indeed, metformin and phenformin and the TGF-β-induced EMT. Growing evidence has emerged that metformin combined with targeted drugs overcomes resistance and enhances therapeutic efficacy. 32 For example, metformin increases the sensitivity of tyrosine kinase inhibitor-resistant lung cancer cells through inhibition of interleukin-6/STAT3 signaling and EMT reversal. 33 According to a recent study, constitutively active STAT3 or silencing of STAT3 regulates metformin-induced growth inhibition and apoptosis in triple-negative breast cancer cells. 34 Our data also In this study, we found that the metformin-and phenforminmediated EMT occurred via TGF-β rather than STAT3 activation.
Metformin has been shown to inhibit the TGF-β1-induced EMT, which plays a key role in cancer progression. 38 Xiao et al 39 silencing by promoter hypermethylation in prostate cancer. 44 Moreover, miR-93 and miR-204, which are aberrantly expressed in various malignant tumors, including prostate and breast cancers, respectively, regulate cancer progression by targeting TGFBR2. 41, 45 Taken together, our findings suggested that metformin and phenformin may regulate TGFBR2 mRNA expression through other regulators. Further studies are needed to clarify the exact mechanisms of TGFBR2 mRNA regulation by metformin and phenformin.
The use of metformin in rectal cancer has recently been reported to significantly improve pathologic complete response rates and survival rates, suggesting the need for prospective studies. 43 Previous studies have shown that low expression of TGFBR2 is related to a poor prognosis in some cancers, including oral, 46 cervical 47 and breast cancers. 28 In contrast, another study suggested that high expression of TGFBR2 may be a poor prognostic indicator for overall survival in estrogen receptor α-negative breast cancer. 48 Li et al 49 also showed that zinc finger protein 32, an important transcription factor associated with cancer, binds to the TGFBR2 promoter and elevates its expression at the mRNA and protein levels, thereby increasing drug resistance in lung cancer. Consistent with this, our results showed that TGFBR2 was highly expressed in rectal cancer cells and tissues. Taken together, our findings supported the oncogenic roles of phospho-STAT3 (Ser-727) and TGFBR2 in rectal cancer progression. These results could have important implications regarding the critical roles of phospho-STAT3 (Ser-727) and TGFBR2
in tumor development through metformin-and phenformin-induced inhibition of apoptosis and the EMT.
In this study, we demonstrated that metformin and phenformin regulated chemoresistance in rectal cancer cells by controlling cell growth and the EMT via phospho-STAT3 (Ser-727) and TGFBR2.
These findings provide insight into the oncogenic activities of phospho-STAT3 (Ser-727) and TGFBR2 and support that metformin and phenformin may have therapeutic roles in rectal cancer treatment.
Moreover, TGFBR2 may represent a promising molecular target for controlling the resistance of rectal cancer to chemotherapy.
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